PubMed:21921061 JSON TXT

Annnotations TAB JSON ListView MergeView

Glycan-Motif

GlyCosmos6-Glycan-Motif-Image

GlyCosmos6-Glycan-Motif-Structure

Glycosmos6-GlycoEpitope

{"project":"Glycosmos6-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":0,"end":8},"obj":"http://www.glycoepitope.jp/epitopes/AN0713"},{"id":"T2","span":{"begin":5,"end":8},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"T3","span":{"begin":9,"end":13},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"T4","span":{"begin":85,"end":88},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"T5","span":{"begin":89,"end":93},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"T6","span":{"begin":326,"end":329},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"T7","span":{"begin":330,"end":334},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"T8","span":{"begin":634,"end":637},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"T9","span":{"begin":638,"end":641},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"T10","span":{"begin":646,"end":650},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"T11","span":{"begin":651,"end":655},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"T12","span":{"begin":759,"end":762},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"T13","span":{"begin":763,"end":767},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"T14","span":{"begin":1194,"end":1197},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"T15","span":{"begin":1219,"end":1223},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

ICD10

{"project":"ICD10","denotations":[{"id":"T1","span":{"begin":174,"end":197},"obj":"http://purl.bioontology.org/ontology/ICD10/G61.0"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GlycoBiology-FMA

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":22,"end":32},"obj":"FMAID:167180"},{"id":"_T2","span":{"begin":139,"end":149},"obj":"FMAID:167180"},{"id":"_T3","span":{"begin":259,"end":271},"obj":"FMAID:82816"},{"id":"_T4","span":{"begin":259,"end":271},"obj":"FMAID:196811"},{"id":"_T5","span":{"begin":275,"end":286},"obj":"FMAID:196811"},{"id":"_T6","span":{"begin":275,"end":286},"obj":"FMAID:82816"},{"id":"_T7","span":{"begin":342,"end":353},"obj":"FMAID:82816"},{"id":"_T8","span":{"begin":342,"end":353},"obj":"FMAID:196811"},{"id":"_T9","span":{"begin":406,"end":421},"obj":"FMAID:196731"},{"id":"_T10","span":{"begin":406,"end":421},"obj":"FMAID:82742"},{"id":"_T11","span":{"begin":459,"end":467},"obj":"FMAID:67745"},{"id":"_T12","span":{"begin":459,"end":467},"obj":"FMAID:165656"},{"id":"_T13","span":{"begin":656,"end":665},"obj":"FMAID:165656"},{"id":"_T14","span":{"begin":656,"end":665},"obj":"FMAID:67745"},{"id":"_T15","span":{"begin":726,"end":738},"obj":"FMAID:82816"},{"id":"_T16","span":{"begin":726,"end":738},"obj":"FMAID:196811"},{"id":"_T17","span":{"begin":848,"end":863},"obj":"FMAID:82742"},{"id":"_T18","span":{"begin":848,"end":863},"obj":"FMAID:196731"},{"id":"_T19","span":{"begin":864,"end":874},"obj":"FMAID:167180"},{"id":"_T20","span":{"begin":904,"end":920},"obj":"FMAID:196731"},{"id":"_T21","span":{"begin":904,"end":920},"obj":"FMAID:82742"},{"id":"_T22","span":{"begin":977,"end":987},"obj":"FMAID:167180"},{"id":"_T23","span":{"begin":1248,"end":1263},"obj":"FMAID:196731"},{"id":"_T24","span":{"begin":1248,"end":1263},"obj":"FMAID:82742"},{"id":"_T25","span":{"begin":1286,"end":1297},"obj":"FMAID:196811"},{"id":"_T26","span":{"begin":1286,"end":1297},"obj":"FMAID:82816"},{"id":"_T27","span":{"begin":1343,"end":1351},"obj":"FMAID:167180"},{"id":"_T28","span":{"begin":1423,"end":1435},"obj":"FMAID:196811"},{"id":"_T29","span":{"begin":1423,"end":1435},"obj":"FMAID:82816"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

uniprot-human

{"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":296,"end":299},"obj":"http://www.uniprot.org/uniprot/P56915"},{"id":"T2","span":{"begin":442,"end":445},"obj":"http://www.uniprot.org/uniprot/P56915"},{"id":"T3","span":{"begin":998,"end":1001},"obj":"http://www.uniprot.org/uniprot/P56915"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GlycoBiology-NCBITAXON

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":888,"end":895},"obj":"http://purl.bioontology.org/ontology/STY/T096"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GO-BP

{"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":40,"end":44},"obj":"http://purl.obolibrary.org/obo/GO_0004617"},{"id":"T2","span":{"begin":479,"end":483},"obj":"http://purl.obolibrary.org/obo/GO_0004617"},{"id":"T3","span":{"begin":805,"end":809},"obj":"http://purl.obolibrary.org/obo/GO_0004617"},{"id":"T4","span":{"begin":833,"end":842},"obj":"http://purl.obolibrary.org/obo/GO_0032502"},{"id":"T5","span":{"begin":967,"end":976},"obj":"http://purl.obolibrary.org/obo/GO_0032502"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GO-MF

{"project":"GO-MF","denotations":[{"id":"T1","span":{"begin":22,"end":32},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T2","span":{"begin":139,"end":149},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T3","span":{"begin":864,"end":874},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T4","span":{"begin":977,"end":987},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T5","span":{"begin":1343,"end":1351},"obj":"http://purl.obolibrary.org/obo/GO_0003823"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GO-CC

{"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":296,"end":299},"obj":"http://purl.obolibrary.org/obo/GO_0032593"},{"id":"T2","span":{"begin":442,"end":445},"obj":"http://purl.obolibrary.org/obo/GO_0032593"},{"id":"T3","span":{"begin":998,"end":1001},"obj":"http://purl.obolibrary.org/obo/GO_0032593"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

Allie

{"project":"Allie","denotations":[{"id":"SS1_21921061_1_0","span":{"begin":174,"end":197},"obj":"expanded"},{"id":"SS2_21921061_1_0","span":{"begin":199,"end":202},"obj":"abbr"},{"id":"SS1_21921061_1_1","span":{"begin":275,"end":294},"obj":"expanded"},{"id":"SS2_21921061_1_1","span":{"begin":296,"end":299},"obj":"abbr"}],"relations":[{"id":"AE1_21921061_1_0","pred":"abbreviatedTo","subj":"SS1_21921061_1_0","obj":"SS2_21921061_1_0"},{"id":"AE1_21921061_1_1","pred":"abbreviatedTo","subj":"SS1_21921061_1_1","obj":"SS2_21921061_1_1"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

sentences

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":94},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":95,"end":301},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":302,"end":446},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":447,"end":601},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":602,"end":739},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":740,"end":1002},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":1003,"end":1359},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1360,"end":1576},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":94},"obj":"Sentence"},{"id":"T2","span":{"begin":95,"end":301},"obj":"Sentence"},{"id":"T3","span":{"begin":302,"end":446},"obj":"Sentence"},{"id":"T4","span":{"begin":447,"end":601},"obj":"Sentence"},{"id":"T5","span":{"begin":602,"end":739},"obj":"Sentence"},{"id":"T6","span":{"begin":740,"end":1002},"obj":"Sentence"},{"id":"T7","span":{"begin":1003,"end":1359},"obj":"Sentence"},{"id":"T8","span":{"begin":1360,"end":1576},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":94},"obj":"Sentence"},{"id":"T2","span":{"begin":95,"end":301},"obj":"Sentence"},{"id":"T3","span":{"begin":302,"end":446},"obj":"Sentence"},{"id":"T4","span":{"begin":447,"end":601},"obj":"Sentence"},{"id":"T5","span":{"begin":602,"end":739},"obj":"Sentence"},{"id":"T6","span":{"begin":740,"end":1002},"obj":"Sentence"},{"id":"T7","span":{"begin":1003,"end":1359},"obj":"Sentence"},{"id":"T8","span":{"begin":1360,"end":1576},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GlycoBiology-Epitope

{"project":"GlycoBiology-Epitope","denotations":[{"id":"PD-GlycoEpitope-B_T1","span":{"begin":5,"end":8},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"PD-GlycoEpitope-B_T2","span":{"begin":85,"end":88},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"PD-GlycoEpitope-B_T3","span":{"begin":326,"end":329},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"PD-GlycoEpitope-B_T4","span":{"begin":634,"end":637},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"PD-GlycoEpitope-B_T5","span":{"begin":638,"end":641},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"PD-GlycoEpitope-B_T6","span":{"begin":759,"end":762},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"PD-GlycoEpitope-B_T7","span":{"begin":1194,"end":1197},"obj":"http://www.glycoepitope.jp/epitopes/EP0050"},{"id":"PD-GlycoEpitope-B_T8","span":{"begin":0,"end":8},"obj":"http://www.glycoepitope.jp/epitopes/AN0713"},{"id":"PD-GlycoEpitope-B_T9","span":{"begin":9,"end":13},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"PD-GlycoEpitope-B_T10","span":{"begin":89,"end":93},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"PD-GlycoEpitope-B_T11","span":{"begin":330,"end":334},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"PD-GlycoEpitope-B_T12","span":{"begin":646,"end":650},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"PD-GlycoEpitope-B_T13","span":{"begin":651,"end":655},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"PD-GlycoEpitope-B_T14","span":{"begin":763,"end":767},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"},{"id":"PD-GlycoEpitope-B_T15","span":{"begin":1219,"end":1223},"obj":"http://www.glycoepitope.jp/epitopes/EP0056"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GlyTouCan-IUPAC

mondo_disease

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":36,"end":39},"obj":"Disease"},{"id":"T2","span":{"begin":174,"end":197},"obj":"Disease"},{"id":"T3","span":{"begin":199,"end":202},"obj":"Disease"},{"id":"T4","span":{"begin":489,"end":492},"obj":"Disease"},{"id":"T5","span":{"begin":815,"end":818},"obj":"Disease"},{"id":"T6","span":{"begin":954,"end":957},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

Glycan-GlyCosmos

GlyCosmos-GlycoEpitope

GlyCosmos15-MONDO

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T1","span":{"begin":36,"end":39},"obj":"Disease"},{"id":"T2","span":{"begin":174,"end":197},"obj":"Disease"},{"id":"T3","span":{"begin":199,"end":202},"obj":"Disease"},{"id":"T4","span":{"begin":489,"end":492},"obj":"Disease"},{"id":"T5","span":{"begin":815,"end":818},"obj":"Disease"},{"id":"T6","span":{"begin":954,"end":957},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GlyCosmos15-NCBITAXON

{"project":"GlyCosmos15-NCBITAXON","denotations":[{"id":"T1","span":{"begin":799,"end":804},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GlyCosmos15-UBERON

{"project":"GlyCosmos15-UBERON","denotations":[{"id":"T1","span":{"begin":527,"end":532},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000119"},{"id":"A2","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0022303"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

sentences

GlyCosmos15-Sentences

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T1","span":{"begin":0,"end":94},"obj":"Sentence"},{"id":"T2","span":{"begin":95,"end":301},"obj":"Sentence"},{"id":"T3","span":{"begin":302,"end":446},"obj":"Sentence"},{"id":"T4","span":{"begin":447,"end":601},"obj":"Sentence"},{"id":"T5","span":{"begin":602,"end":739},"obj":"Sentence"},{"id":"T6","span":{"begin":740,"end":1002},"obj":"Sentence"},{"id":"T7","span":{"begin":1003,"end":1359},"obj":"Sentence"},{"id":"T8","span":{"begin":1360,"end":1576},"obj":"Sentence"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

GlyCosmos15-Glycan

GlyCosmos15-GlycoEpitope

NCBITAXON

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":799,"end":804},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}

Anatomy-UBERON

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":527,"end":532},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000119"},{"id":"A2","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0022303"}],"text":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a.\nIt is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies."}